- Alzamend Neuro Inc ALZN submitted an investigational new drug application to the FDA for its immunotherapy candidate, ALZN002.
- The product candidate is designed to treat mild to moderate dementia of the Alzheimer’s type.
- ALZN002 is a proprietary “active” immunotherapy product, which means each patient’s immune system produces it.
- It consists of autologous dendritic cells (DCs) that are activated white blood cells taken from each patient so that they can be engineered outside of the body to attack Alzheimer’s-related amyloid-beta proteins.
- Related: These Stocks Are On The Radar After Biogen-Eisai’s Surprising Alzheimer’s Trial Win.
- These DCs are pulsed with a novel amyloid-beta peptide designed to bolster the ability of the patient’s immune system to combat Alzheimer’s.
- The ALZN002-01 Phase 1/2A trial will assess the safety, tolerability, and efficacy of multiple ascending doses of ALZN002 compared to placebo in 20‑30 subjects with mild to moderate dementia of the Alzheimer’s type.
- Price Action: ALZN shares are down 6.78% at $1.10 on the last check Thursday.